Research and Development

Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined …

Rare disease specialist pharma firm Shire, rare disease patient alliance EURORDIS and tech giant Microsoft have announced they have formed …

The sometimes poor efficacy of influenza vaccines may be due to poor immune response and a patient’s wider immune history, …

Unleash Immuno Oncolytics, a US firm focusing on the development of viral biologics in the treatment of cancer, has attracted …

Pharmafocus talks to John Ellwood about the challenges of being diagnosed with multiple myeloma and how having a strong support …

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …

Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …

Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …

Researchers at the Roswell Park Comprehensive Cancer Centre in New York have published findings indicating that ovarian cancer risk may …

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …

AliveCor has announced that it has begun the rollout of its KardiaMobile technology to the NHS via the UK’s Academic …

MSD has announced plans to invest in a new biotechnology facility in Dublin which it claims will create 350 jobs …

The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …

Another blow has been dealt to the field of Alzheimer’s research as MSD announces yet another trial failure of a …

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …